Medical Condition News

RSS

FDA grants Fast Track designation for ARCA biopharma's Gencaro

ARCA biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of GencaroTM, the Company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, for the reduction of cardiovascular mortality and cardiovascular hospitalizations in a genotype-defined heart failure population.

23 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.

23 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Most Canadians hope OAB symptoms will go away

A recent poll conducted by Leger Marketing, on behalf of the Powder Room - a national education program for those with overactive bladder (OAB) - asked 1,500 Canadians about their bladder health. The findings revealed that although people are experiencing OAB symptoms, most are choosing not to seek medical attention - perhaps assuming the frustrating and embarrassing symptoms will go away, or that they will just have to live with them.

23 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Cellular prion protein and epileptic seizures: researchers find new role

Cellular prion protein (PrPc) plays an essential role in maintaining neurotransmitter homeostasis in the central nervous system. This discovery has been made possible by the observation that both a deficiency and an excess of the protein have a considerable effect on this homeostasis.

23 Nov 2009

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.

23 Nov 2009

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Fred Hutchinson Cancer Research Center has received a pledge of $10 million to advance the promising field of immunotherapy research to treat and cure cancer, even in late stages.

23 Nov 2009

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

The 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 – will take place from March 9th to13th 2010 in the Auditorium Tract of the Ludwig-Maximilians-University, Campus Grosshadern, in Munich/Germany.

23 Nov 2009

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells.

23 Nov 2009

Overexpression of NCX1 does not by itself lead to contraction abnormalities in the heart

Researchers from the Center for Translational Medicine at Thomas Jefferson University have found that the overexpression of a sodium/calcium exchanger, without changes in other ion transport pathways commonly observed in heart failure, does not by itself lead to contraction abnormalities in the heart.

23 Nov 2009

Medical Condition News

FDA grants Fast Track designation for ARCA biopharma's Gencaro

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

Most Canadians hope OAB symptoms will go away

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Kingston University receives £99,000 for cancer research

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Cellular prion protein and epileptic seizures: researchers find new role

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Fred Hutchinson Cancer Research Center receives $10 million to advance biomedical research

Medical students and biomedical scientists to attend 8th World Congress on Trauma, Shock, Inflammation and Sepsis

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Overexpression of NCX1 does not by itself lead to contraction abnormalities in the heart

Winship-led team identifies a way to exploit cancer cells' taste for glucose

Study examines how dietary restriction and high-caloric diet influence biochemical responses

Renal transplant nurses can play a key role in enhancing patients' quality of life

UT Southwestern Medical Center receives NIH funds for asthma research

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News